Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients
BackgroundFasciola hepatica, a globally distributed helminth, causes fasciolosis, a disease with significant health and economic impacts. Variability in triclabendazole (TCBZ) efficacy and emerging resistance are remaining challenges. Evidence suggests that the gut microbiome influences host-helmint...
| Published in: | Frontiers in Cellular and Infection Microbiology |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1555171/full |
| _version_ | 1849747479181918208 |
|---|---|
| author | Giljae Lee Bruce A. Rosa Martha V. Fernandez-Baca John Martin Rodrigo A. Ore Pedro Ortiz Miguel M. Cabada Miguel M. Cabada Makedonka Mitreva Makedonka Mitreva Makedonka Mitreva |
| author_facet | Giljae Lee Bruce A. Rosa Martha V. Fernandez-Baca John Martin Rodrigo A. Ore Pedro Ortiz Miguel M. Cabada Miguel M. Cabada Makedonka Mitreva Makedonka Mitreva Makedonka Mitreva |
| author_sort | Giljae Lee |
| collection | DOAJ |
| container_title | Frontiers in Cellular and Infection Microbiology |
| description | BackgroundFasciola hepatica, a globally distributed helminth, causes fasciolosis, a disease with significant health and economic impacts. Variability in triclabendazole (TCBZ) efficacy and emerging resistance are remaining challenges. Evidence suggests that the gut microbiome influences host-helminth interactions and is associated with anthelmintic effects, but its association with human F. hepatica infection and TCBZ efficacy is not well understood.MethodsIn this study, we investigated the relationship between Fasciola hepatica infection and the gut microbiome through metagenomic shotgun sequencing of 30 infected and 60 age- and sex-matched uninfected individuals from Peru. Additionally, we performed a longitudinal analysis to evaluate microbiome dynamics in relation to TCBZ treatment response.Results and discussionInfection was associated with specific microbial taxonomic and functional features, including higher abundance of Negativibacillus sp900547015, Blautia A sp000285855, and Prevotella sp002299635 species, and enrichment of microbial pathways linked to survival under stress and depletion of pathways for microbial growth. Unexpectedly, we identified that responders to TCBZ treatment (who cleared infection) harbored many microbiome features significantly different relative to non-responders, both before and after treatment. Specifically, the microbiomes of responders had a higher abundance Firmicutes A and Bacteroides species as well as phospholipid synthesis and glucuronidation pathways, while non-responders had higher abundance of Actinobacteria species including several from the Parolsenella and Bifidobacterium genera, and Bifidobacterium shunt and amino acid biosynthesis pathways.ConclusionsOur findings underscore the impact of helminth infection on gut microbiome and suggest a potential role of gut microbiota in modulating TCBZ efficacy, offering novel insights into F. hepatica-microbiome interactions and paving the way for microbiome-informed treatment approaches. |
| format | Article |
| id | doaj-art-e4898fba808b401b88a87ca470df1add |
| institution | Directory of Open Access Journals |
| issn | 2235-2988 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| spelling | doaj-art-e4898fba808b401b88a87ca470df1add2025-08-20T01:40:41ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-03-011510.3389/fcimb.2025.15551711555171Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patientsGiljae Lee0Bruce A. Rosa1Martha V. Fernandez-Baca2John Martin3Rodrigo A. Ore4Pedro Ortiz5Miguel M. Cabada6Miguel M. Cabada7Makedonka Mitreva8Makedonka Mitreva9Makedonka Mitreva10Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United StatesDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United StatesDivision of Infectious Diseases, Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX, United StatesDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United StatesSede Cusco, Instituto de Medicina Tropical “Alexander von Humboldt”, Universidad Peruana Cayetano Heredia, Cusco, PeruFaculty of Veterinary Science, Universidad Nacional de Cajamarca, Cajamarca, PeruDivision of Infectious Diseases, Department of Internal Medicine, The University of Texas Medical Branch, Galveston, TX, United StatesSede Cusco, Instituto de Medicina Tropical “Alexander von Humboldt”, Universidad Peruana Cayetano Heredia, Cusco, PeruDivision of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United StatesDepartment of Genetics, Washington University School of Medicine, St. Louis, MO, United StatesMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, United StatesBackgroundFasciola hepatica, a globally distributed helminth, causes fasciolosis, a disease with significant health and economic impacts. Variability in triclabendazole (TCBZ) efficacy and emerging resistance are remaining challenges. Evidence suggests that the gut microbiome influences host-helminth interactions and is associated with anthelmintic effects, but its association with human F. hepatica infection and TCBZ efficacy is not well understood.MethodsIn this study, we investigated the relationship between Fasciola hepatica infection and the gut microbiome through metagenomic shotgun sequencing of 30 infected and 60 age- and sex-matched uninfected individuals from Peru. Additionally, we performed a longitudinal analysis to evaluate microbiome dynamics in relation to TCBZ treatment response.Results and discussionInfection was associated with specific microbial taxonomic and functional features, including higher abundance of Negativibacillus sp900547015, Blautia A sp000285855, and Prevotella sp002299635 species, and enrichment of microbial pathways linked to survival under stress and depletion of pathways for microbial growth. Unexpectedly, we identified that responders to TCBZ treatment (who cleared infection) harbored many microbiome features significantly different relative to non-responders, both before and after treatment. Specifically, the microbiomes of responders had a higher abundance Firmicutes A and Bacteroides species as well as phospholipid synthesis and glucuronidation pathways, while non-responders had higher abundance of Actinobacteria species including several from the Parolsenella and Bifidobacterium genera, and Bifidobacterium shunt and amino acid biosynthesis pathways.ConclusionsOur findings underscore the impact of helminth infection on gut microbiome and suggest a potential role of gut microbiota in modulating TCBZ efficacy, offering novel insights into F. hepatica-microbiome interactions and paving the way for microbiome-informed treatment approaches.https://www.frontiersin.org/articles/10.3389/fcimb.2025.1555171/fullliver flukeFasciola hepaticatriclabendazoletreatment responseintestinal microbiomemetagenomic shotgun sequencing |
| spellingShingle | Giljae Lee Bruce A. Rosa Martha V. Fernandez-Baca John Martin Rodrigo A. Ore Pedro Ortiz Miguel M. Cabada Miguel M. Cabada Makedonka Mitreva Makedonka Mitreva Makedonka Mitreva Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients liver fluke Fasciola hepatica triclabendazole treatment response intestinal microbiome metagenomic shotgun sequencing |
| title | Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients |
| title_full | Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients |
| title_fullStr | Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients |
| title_full_unstemmed | Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients |
| title_short | Distinct gut microbiome features characterize Fasciola hepatica infection and predict triclabendazole treatment outcomes in Peruvian patients |
| title_sort | distinct gut microbiome features characterize fasciola hepatica infection and predict triclabendazole treatment outcomes in peruvian patients |
| topic | liver fluke Fasciola hepatica triclabendazole treatment response intestinal microbiome metagenomic shotgun sequencing |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1555171/full |
| work_keys_str_mv | AT giljaelee distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients AT brucearosa distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients AT marthavfernandezbaca distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients AT johnmartin distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients AT rodrigoaore distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients AT pedroortiz distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients AT miguelmcabada distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients AT miguelmcabada distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients AT makedonkamitreva distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients AT makedonkamitreva distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients AT makedonkamitreva distinctgutmicrobiomefeaturescharacterizefasciolahepaticainfectionandpredicttriclabendazoletreatmentoutcomesinperuvianpatients |
